Polpharma Has a New CEO
(Thomson Reuters ONE) -
STAROGARD GDANSKI, Poland -- On 8 October 2015, Dr Maurice Chagnaud will be
appointed as the new Chief Executive Officer of Polpharma, the largest Polish
pharmaceutical group. Dr Chagnaud, who has over twenty years' experience in top
management positions in the European pharmaceutical industry, is expected to
further accelerate the development of Polpharma to become a regional leader in
CEE, CIS and Central Asia.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/793d84b7-01d5-4bc5-a149-
db9dcd51e65c
The Polpharma Group is among the top 20 generic drug manufacturers in the world.
It is a leading generics player based in Poland, operating across Europe, CIS
and Central Asia, with manufacturing subsidiaries in Poland, Russia and
Kazakhstan. It actively invests in biologics, building a strong internal
organization as well as external partnerships for global development and the
commercialization of biosimilars.
"Polpharma's strategic goal is to become a regional leader and grow outside of
our current boundaries. We are impressed by the extensive experience of Mr
Chagnaud, gained in international companies such as Merck Generics, Teva and
Lupin, where his achievements included building regional strategies and
transforming organizations to meet new challenges. I am confident that he will
manage Polpharma effectively, identify and pursue new opportunities, and
motivate our team to deliver outstanding performance to secure the long-term
growth of our group," says Jerzy Starak, Chairman of Polpharma's Supervisory
Board.
Maurice Chagnaud has over 20 years' experience in generics, OTC medicines, and
biosimilars gained in international companies, where his achievements included
building regional strategies and transforming organizations to meet new
challenges. He worked for Merck Generics (Merck KgAa) for twelve years,
responsible for its all commercial operations (retail, hospital and export) in
France and as General Manager of Merck Generics Italia. Over the next seven
years, he held several positions at TEVA: he was General Manager of TEVA and
Ivax France, Chief Commercial Officer of TEVA Europe, and Senior Vice President
in Central and Eastern Europe, running several acquisitions and integrations of
companies. More recently, he served as President Europe - Russia & CIS and
Global Head of Inhalation Strategy at Lupin, where he developed a European
strategy including new geographies, reshaping the portfolio, and new commercial
initiatives. He is a doctor of medicine, and holds an MBA degree in marketing,
finance and administration.
As the new CEO of Polpharma, Dr Chagnaud will succeed Markus Sieger, who has
been delegated by the Supervisory Board to exercise supervision over the company
for the last six months, and who will remain a Member of Polpharma's Supervisory
Board.
About Polpharma Group
Polpharma Group is a leading generics player based in Poland, operating across
Europe, the Caucasus and Central Asia, with manufacturing subsidiaries in
Poland, Russia and Kazakhstan. It is among the top 20 generic drug manufacturers
in the world with annual sales of approximately $1 billion. The Polpharma Group
portfolio includes nearly 600 products with another 200 in development. It is
also one of the leading European API producers, delivering products for
pharmaceutical companies worldwide. In order to provide patients with more
affordable access to modern biologic drugs, Polpharma Group has decided to focus
on biosimilar products. It has created a state-of-the-art R&D and production
centre and established strategic partnerships in addition to expanding its
capabilities in the development and commercialization of biosimilars. For more
information visit the Polpharma Group website at www.polpharma.pl/en.
Contact information
Magdalena Rzeszotalska, Corporate Communications and CSR Director, Polpharma,
phone: +48 607 696 473, magdalena.rzeszotalska(at)polpharma.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Polpharma via GlobeNewswire
[HUG#1955039]
Datum: 28.09.2015 - 22:48 Uhr
Sprache: Deutsch
News-ID 423136
Anzahl Zeichen: 4929
contact information:
Town:
Staraogard Gdanski
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 256 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Polpharma Has a New CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
Polpharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
